Reported resultsCompany-reported
What was reported
BURLINGTON, Mass. and JERUSALEM, Aug. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported its second quarter 2026 financial results and provided an operational update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 6-K · Aug 12, 2026 · Open the source ↗
What the evidence supports
BrainsWay published its results for the period in a press release furnished to the SEC (Form 6-K).
What remains unknown
Audit status of the figures (results furnished on Form 8-K or 6-K are typically unaudited), and anything about future periods. Any outlook is the company's own projection. Figures and claims are the company's own description and have not been independently verified.
Figures as stated
Numbers exactly as written in the source. We don’t annualise, convert or add them up.
| Figure | In context |
|---|---|
| $17.1 million | “Revenue in the second quarter of 2026 increased 35% to $17.1 million, compared with $12.6 million in the second quarter of 2025.” Mentions: revenue |
| $12.6 million | “Revenue in the second quarter of 2026 increased 35% to $17.1 million, compared with $12.6 million in the second quarter of 2025.” Mentions: revenue |
| $80.4 million | “Remaining performance obligations (RPOs) rose to $80.4 million as of June 30, 2026, a 30% increase compared with the same period last year.” |
Source passages
Exact excerpts from the source, with links. Quotes are checked character for character against our stored copy.
Press release headlineBrainsWay Reports Second Quarter 2026 Financial Results and Operational HighlightsU.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 6-K · Aug 12, 2026 · Open the source ↗
Press release lead paragraphBURLINGTON, Mass. and JERUSALEM, Aug. 12, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported its second quarter 2026 financial results and provided an operational update.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 6-K · Aug 12, 2026 · Open the source ↗
Amount stated in press releaseRevenue in the second quarter of 2026 increased 35% to $17.1 million, compared with $12.6 million in the second quarter of 2025.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 6-K · Aug 12, 2026 · Open the source ↗
Amount stated in press releaseRemaining performance obligations (RPOs) rose to $80.4 million as of June 30, 2026, a 30% increase compared with the same period last year.U.S. Securities and Exchange Commission (EDGAR) · Exhibit 99.1 to 6-K · Aug 12, 2026 · Open the source ↗
Revision history
- Revision 1 · Oct 28, 2026, 20:53 UTC
BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights
Spotted an error? Tell us. Corrections are published, never silent: see all corrections.